Report provides in-depth analysis of the pipeline molecules, clinical trial failure rates, and recent deals. The report has been built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis carried out by Research’s team of industry experts.
Albany, NY -- (SBWIRE) -- 02/09/2016 -- Type 2 diabetes is a major public health concerns in both the developed as well as the developing countries in the Asia Pacific. According to the International Diabetes Federation, nearly 387 million people around the world have diabetes and majority of these cases will be Type 2 diabetes. By 2035, the world will have nearly 592 million diabetics and at least 60% of it will be from Asia Pacific. Type 2 diabetes, once considered a disease of affluence and known to affecting people from the more industrialized parts of the world, is rapidly reaching epidemic proportions in Asia Pacific where malnutrition and infectious diseases were the major health concerns up until the last decade.
Complete Report with TOC @ http://www.mrrse.com/type-2-diabetes-therapeutics-in-asia-pacific-markets
The Asia Pacific region is home to one third of the entire world\'s population, and includes numerous ethnic groups. The region is observing rapid socioeconomic changes and rising urbanization is leading to lifestyle changes that largely trigger type 2 diabetes. Thus, the prevalence of type 2 is particularly high in newly industrialized parts. The direct and indirect costs of treating diabetes and the numerous complications related with it have the potential of crippling the healthcare budgets of developing countries of Asia Pacific. Knowing that the world spent more than US$610 billion in diabetes therapeutics and diabetes led to the death of nearly 4.9 million deaths in 2014, the fact that 60% of the global diabetics are from Asia Pacific makes the critical nature of diabetes in Asia Pacific quite clear. it is estimated that nearly 90% of the overall cases of diabetes observed in Asia Pacific are of Type 2 diabetes. The therapeutics market of type 2 diabetes in Asia Pacific is huge and is escalating at exceedingly high rates.
The report analyzes the treatment use patterns, market characterization, pipeline analysis and key licensing and co-development deals of the type 2 diabetes in the APAC markets of China, India, Japan, and Australia.It includes
A brief introduction to type 2 diabetes, including its pathophysiology, etiology, diagnosis and treatment algorithms
In-depth analysis of currently marketed drugs for type 2 diabetes, including analysis of their safety, efficacy, treatment patterns, and strengths and weaknesses, as well as a heat map comparing them in terms of safety and efficacy
A comprehensive review of the pipeline for type 2 diabetes, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period; the pipeline is analyzed by Phase distribution, molecule type, program type, mechanism of action and molecular target
Additional in-depth analysis of pipeline drug clinical trials by Phase, trial size, trial duration and program failure rate for each molecule type
Multi-scenario market forecast data to 2020, taking into account how the market might be affected by the introduction of new drugs, the expiry of key patents on current drugs, and the changes in disease epidemiology across the key developed markets
Discussion of the drivers of and barriers to market growth
In-depth analysis of all licensing and co-development deals that have occurred in the type 2 diabetes market since 2006
Request a Free Sample Copy of the Report @ http://www.mrrse.com/sample/130
MRRSE stands for Market Research Reports Search Engine, the largest online catalog of latest market research reports based on industries, companies, and countries. MRRSE sources thousands of industry reports, market statistics, and company profiles from trusted entities and makes them available at a click. Besides well-known private publishers, the reports featured on MRRSE typically come from national statistics agencies, investment agencies, leading media houses, trade unions, governments, and embassies.